Hansa Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 4.95 million compared to SEK 0.762 million a year ago. Net loss was SEK 148.37 million compared to SEK 122.41 million a year ago. Basic loss per share from continuing operations was SEK 3.34 compared to SEK 2.77 a year ago. Diluted loss per share from continuing operations was SEK 3.34 compared to SEK 2.77 a year ago. For the nine months, sales was SEK 18.48 million compared to SEK 2.27 million a year ago. Net loss was SEK 384.89 million compared to SEK 315.02 million a year ago. Basic loss per share from continuing operations was SEK 8.65 compared to SEK 7.61 a year ago. Diluted loss per share from continuing operations was SEK 8.65 compared to SEK 7.61 a year ago.